Sarah S Bernards1, Kathryn P Pennington2, Maria I Harrell3, Kathy J Agnew4, Rochelle L Garcia5, Barbara M Norquist6, Elizabeth M Swisher7. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: sarahb18@uw.edu. 2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: katypenn@uw.edu. 3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: maribel@uw.edu. 4. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: kagnew@uw.edu. 5. Department of Pathology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: rochelle@uw.edu. 6. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: bnorquis@uw.edu. 7. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: swishere@uw.edu.
Abstract
OBJECTIVE: In ovarian carcinoma, mutations in homologous recombination DNA repair (HRR) genes, including BRCA1 and RAD51C, are associated with increased survival and specific clinical features. Promoter hypermethylation is another mechanism of reducing gene expression. We assessed whether BRCA1 and RAD51C promoter hypermethylation is associated with similar survival and clinical characteristics. METHODS: Promoter methylation of BRCA1 and RAD51C was evaluated using methylation-sensitive PCR in 332 primary ovarian carcinomas. Damaging germline and somatic mutations in 16 HRR genes were identified using BROCA sequencing. RESULTS: BRCA1 methylation was detected in 22 carcinomas (6.6%) and RAD51C methylation in 9 carcinomas (2.7%). These small numbers limited the power to detect differences in survival and platinum sensitivity. Mutations in one or more HRR genes were found in 95 carcinomas (29%). Methylation of BRCA1 or RAD51C was mutually exclusive with mutations in these genes (P=0.001). Patients whose carcinomas had BRCA1 methylation (57.7years±2.5) or BRCA1 mutations (54.1years±1.4) were younger than those without (63.3years±0.8; P=0.029, P<0.0001). BRCA1 methylation and germline BRCA1 mutation were associated with high grade serous (HGS) histology (P=0.045, P=0.001). BRCA1 mutations were associated with increased sensitivity to platinum chemotherapy while BRCA1 methylation was not (P=0.034, P=0.803). Unlike HRR mutations, methylation was not associated with improved overall survival compared to cases without methylation or mutation. CONCLUSIONS: Patients with BRCA1-methylated carcinomas share clinical characteristics with patients with BRCA1-mutated carcinomas including younger age and predominantly HGS histology. However, unlike mutation, RAD51C and BRCA1 methylation were not associated with improved survival or greater sensitivity to platinum chemotherapy.
OBJECTIVE: In ovarian carcinoma, mutations in homologous recombination DNA repair (HRR) genes, including BRCA1 and RAD51C, are associated with increased survival and specific clinical features. Promoter hypermethylation is another mechanism of reducing gene expression. We assessed whether BRCA1 and RAD51C promoter hypermethylation is associated with similar survival and clinical characteristics. METHODS: Promoter methylation of BRCA1 and RAD51C was evaluated using methylation-sensitive PCR in 332 primary ovarian carcinomas. Damaging germline and somatic mutations in 16 HRR genes were identified using BROCA sequencing. RESULTS:BRCA1 methylation was detected in 22 carcinomas (6.6%) and RAD51C methylation in 9 carcinomas (2.7%). These small numbers limited the power to detect differences in survival and platinum sensitivity. Mutations in one or more HRR genes were found in 95 carcinomas (29%). Methylation of BRCA1 or RAD51C was mutually exclusive with mutations in these genes (P=0.001). Patients whose carcinomas had BRCA1 methylation (57.7years±2.5) or BRCA1 mutations (54.1years±1.4) were younger than those without (63.3years±0.8; P=0.029, P<0.0001). BRCA1 methylation and germline BRCA1 mutation were associated with high grade serous (HGS) histology (P=0.045, P=0.001). BRCA1 mutations were associated with increased sensitivity to platinum chemotherapy while BRCA1 methylation was not (P=0.034, P=0.803). Unlike HRR mutations, methylation was not associated with improved overall survival compared to cases without methylation or mutation. CONCLUSIONS:Patients with BRCA1-methylated carcinomas share clinical characteristics with patients with BRCA1-mutated carcinomas including younger age and predominantly HGS histology. However, unlike mutation, RAD51C and BRCA1 methylation were not associated with improved survival or greater sensitivity to platinum chemotherapy.
Authors: Francesca Menghi; Kalyan Banda; Pooja Kumar; Robert Straub; Lacey Dobrolecki; Isabel V Rodriguez; Susan E Yost; Harshpreet Chandok; Marc R Radke; George Somlo; Yuan Yuan; Michael T Lewis; Elizabeth M Swisher; Edison T Liu Journal: Sci Transl Med Date: 2022-07-06 Impact factor: 19.319
Authors: Roshni D Kalachand; Britta Stordal; Stephen Madden; Benjamin Chandler; Julie Cunningham; Ellen L Goode; Ilary Ruscito; Elena I Braicu; Jalid Sehouli; Atanas Ignatov; Herbert Yu; Dionyssios Katsaros; Gordon B Mills; Karen H Lu; Mark S Carey; Kirsten M Timms; Jolanta Kupryjanczyk; Iwona K Rzepecka; Agnieszka Podgorska; Jessica N McAlpine; Elizabeth M Swisher; Sarah S Bernards; Ciaran O'Riain; Sharon O'Toole; John J O'Leary; David D Bowtell; David M Thomas; Katharina Prieske; Simon A Joosse; Linn Woelber; Parvesh Chaudhry; Norman Häfner; Ingo B Runnebaum; Bryan T Hennessy Journal: J Natl Cancer Inst Date: 2020-12-14 Impact factor: 13.506
Authors: Christopher B Morse; Mirna N Toukatly; Mark R Kilgore; Kathy J Agnew; Sarah S Bernards; Barbara M Norquist; Kathryn P Pennington; Rochelle L Garcia; John B Liao; Elizabeth M Swisher Journal: Gynecol Oncol Date: 2019-02-23 Impact factor: 5.304
Authors: Vanessa Rosse de Souza; Adriana Aniceto; Joel Pimentel Abreu; Julia Montenegro; Bruno Boquimpani; Vanessa Azevedo de Jesuz; Monique de Barros Elias Campos; Paulo Sérgio Marcellini; Otniel Freitas-Silva; Rafael Cadena; Anderson Junger Teodoro Journal: Food Sci Nutr Date: 2020-04-15 Impact factor: 2.863
Authors: Rachel M Hurley; Cordelia D McGehee; Ksenija Nesic; Cristina Correia; Taylor M Weiskittel; Rebecca L Kelly; Annapoorna Venkatachalam; Xiaonan Hou; Nicholas M Pathoulas; X Wei Meng; Olga Kondrashova; Marc R Radke; Paula A Schneider; Karen S Flatten; Kevin L Peterson; Marc A Becker; Ee Ming Wong; Melissa S Southey; Alexander Dobrovic; Kevin K Lin; Thomas C Harding; Iain McNeish; Christian A Ross; Jill M Wagner; Matthew J Wakefield; Clare L Scott; Paul Haluska; Andrea E Wahner Hendrickson; Larry M Karnitz; Elizabeth M Swisher; Hu Li; S John Weroha; Scott H Kaufmann Journal: NAR Cancer Date: 2021-07-09
Authors: Elizabeth Santana Dos Santos; François Lallemand; Ambre Petitalot; Sandrine M Caputo; Etienne Rouleau Journal: Int J Mol Sci Date: 2020-05-28 Impact factor: 5.923
Authors: Yan You; Lei Li; Junliang Lu; Huanwen Wu; Jing Wang; Jie Gao; Ming Wu; Zhiyong Liang Journal: Front Oncol Date: 2020-03-10 Impact factor: 6.244